Department of Molecular Epidemiology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.
Center for Information, Jichi Medical University, Tochigi, Japan.
BMC Cancer. 2020 Mar 4;20(1):186. doi: 10.1186/s12885-020-6663-4.
CYP2A6 is an enzyme involved in oxidation of a number of environmental chemicals, including nicotine, pro-carcinogenic nitrosamines and polycyclic aromatic hydrocarbons (PAHs). The whole gene deletion of CYP2A6 (CYP2A64) is prevalent in East Asian population. Whether or not CYP2A64 associates with cancer is still controversial.
We undertook an association study to determine whether deletion of CYP2A6 gene associates with total cancer and major cancer types employing data of consecutive autopsy cases registered in the Japanese single-nucleotide polymorphisms for geriatric research (JG-SNP) database. The presence of cancer were inspected at the time of autopsy and pathologically confirmed. Genotyping for CYP2A6 wild type (W) and deletion (D) was done by allele specific RT-PCR method.
Among 1373 subjects, 826 subjects (60.2%) were cancer positive and 547 subjects (39.8%) were cancer negative. The genotype frequency in the whole study group for WW, WD and DD were 65.0, 30.6 and 4.4%, respectively, which obeyed the Hardy-Weinberg equilibrium (p = 0.20). Total cancer presence, as well as major cancers including gastric, lung, colorectal, and blood cancers did not show any positive association with CYP2A6 deletion. When male and female were separately analyzed, CYP2A6 deletion associated with decreased gastric cancer risk in female (OR = 0.49, 95%CI: 0.25-0.95, p = 0.021, after adjustment for age, smoking and drinking). When smoker and non-smoker were separately analyzed, CYP2A6 deletion associated with decreased total cancer in female nonsmokers (OR = 0.67, 95%CI: 0.45-0.99, p = 0.041 after adjustment). On the other hand, CYP2A6 deletion associated increase blood cancers in smokers (OR = 2.05, 95%CI: 1.19-3.53, p = 0.01 after adjustment).
The CYP2A6 deletion may not grossly affect total cancer. It may associate with individual cancers in sex and smoking dependent manner. Further studies with larger sample size are warranted to confirm our results.
CYP2A6 是一种参与氧化许多环境化学物质的酶,包括尼古丁、前致癌亚硝胺和多环芳烃 (PAHs)。CYP2A6 全基因缺失 (CYP2A64) 在东亚人群中普遍存在。CYP2A64 是否与癌症有关仍存在争议。
我们进行了一项关联研究,以确定 CYP2A6 基因缺失是否与总癌症和主要癌症类型有关,研究数据来自日本单核苷酸多态性老年研究 (JG-SNP) 数据库中连续尸检病例的登记。在尸检时检查癌症的存在,并通过病理学确认。通过等位基因特异性 RT-PCR 方法对 CYP2A6 野生型 (W) 和缺失 (D) 进行基因分型。
在 1373 名受试者中,826 名 (60.2%) 为癌症阳性,547 名 (39.8%) 为癌症阴性。在整个研究组中,WW、WD 和 DD 的基因型频率分别为 65.0%、30.6%和 4.4%,符合 Hardy-Weinberg 平衡 (p=0.20)。总癌症的发生以及包括胃癌、肺癌、结直肠癌和血液癌在内的主要癌症与 CYP2A6 缺失均无明显正相关。当按性别分别分析时,CYP2A6 缺失与女性胃癌风险降低相关 (OR=0.49,95%CI:0.25-0.95,p=0.021,调整年龄、吸烟和饮酒因素后)。当按吸烟者和非吸烟者分别分析时,CYP2A6 缺失与女性非吸烟者总癌症减少相关 (OR=0.67,95%CI:0.45-0.99,p=0.041,调整后)。另一方面,CYP2A6 缺失与吸烟者血液癌的增加相关 (OR=2.05,95%CI:1.19-3.53,p=0.01,调整后)。
CYP2A6 缺失可能不会显著影响总癌症。它可能与性别和吸烟依赖方式的个别癌症有关。需要更大样本量的进一步研究来证实我们的结果。